Corcept's Lifyorli Launch Breaks the Mold: GR Antagonism Goes Beyond Cushing's
A record quarter, a fast-moving oncology launch, and a pipeline that could expand the addressable market five-fold.
CORT · Earnings Call · 2026-07-29
A Quarter That Reframes the Investment Thesis
The market's verdict is already in: Corcept's stock has surged +192% over the past 90 days, reinflating a story that has now compounded at +4,174% since 2010. The trigger is a single word: nenocorilant—no, that's not it. The real driver is patients with ALS… wait, let's start properly. Corcept's Q2 2026 numbers were staggering: revenue of $256 million, up 32% year-over-year, driven by the first full quarter of Lifyorli (relacorilant) in platinum-resistant ovarian cancer. CFO Atabak Mokari opened the call with the headline: “Our revenue in the second quarter of 26 was $256 million a 32% increase over the prior year period.” — Atabak Mokari, Unknown (likely senior management, possibly CFO or investor relations) · 2026-07-29 This was the first quarter that included Lifyorli revenue, and the company raised full-year guidance to $1.1–1.2 billion. The market's response was immediate—the stock nearly tripled in three months. What makes this quarter transformative is not just the revenue beat but the realization that GR antagonism—the science of modulating cortisol activity—has utility far beyond hypercortisolism. Lifyorli's launch is a case study in efficient commercial execution: more than 1,300 patients initiated and 1,000 unique prescribers within the first quarter of availability. Roberto Vieira, President of Oncology, highlighted the momentum: “We have really accelerated the adoption of patients there... we are on our way to become market leaders as well as to realize the potential of $1 billion just for platinum resistant ovarian cancer itself.” — Roberto W. Vieira, President of Oncology · 2026-07-29Lifyorli: A New Standard of Care Taking Shape
The clinical data underpinning Lifyorli is compelling. The pivotal ROSELLA trial met both primary endpoints, showing a 35% reduction in risk of death (hazard ratio 0.65) in all-comer platinum-resistant ovarian cancer. The safety profile is manageable, and the drug is oral—no biomarker required. The NCCN guidelines listed it as a preferred regimen within 15 days of approval, which is unusually fast. This supports broad payer coverage and physician adoption. As Roberto put it, “Lifyorli is on its way to becoming a new standard of care.” — Roberto W. Vieira, President of Oncology · 2026-07-29 The company is also thinking beyond the current indication. The BELLA trial is evaluating relacorilant in platinum-sensitive ovarian, endometrial, and cervical cancers, while STELLA (cervical) and TRIDENT (pancreatic) are underway. Combined with a Phase 1b study of nenocorilant plus nivolumab across solid tumors, the pipeline has the potential to expand the patient pool five-fold. The CEO, Joseph Belanoff, framed it as a platform:Notably, the same molecule, relacorilant, is being resubmitted for Cushing's syndrome with a PDUFA date of December 17, 2026. This dual-track strategy—one asset, two major indications—is underappreciated. In endocrinology, the CATALYST and MOMENTUM trials have revealed that hypercortisolism is far more prevalent than assumed: 24% of difficult-to-treat diabetics and 27% of resistant-hypertension patients have it. Sean Maduck said the company expects Cushing's syndrome revenue to reach $3–5 billion by the end of the decade, a figure that could accelerate with relacorilant's approval.We believe GR antagonism has a broad utility in oncology... Successful results would immediately increase the number of patients that relacorilant may help by 5-fold.